• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Øvrige samlinger
  • Publikasjoner fra CRIStin - NTNU
  • View Item
  •   Home
  • Øvrige samlinger
  • Publikasjoner fra CRIStin - NTNU
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy

Wergeland, Ida; Pullar, Nadine Durema; Assmus, Jörg; Ueland, Thor; Tonby, Kristian; Feruglio, Siri; Kvale, Dag; Damås, Jan Kristian; Aukrust, Pål; Mollnes, Tom Eirik; Dyrhol-Riise, Anne Ma
Journal article, Peer reviewed
Thumbnail
View/Open
1-s2.0-S0163445315000262-main.pdf (1.315Mb)
URI
http://hdl.handle.net/11250/2367653
Date
2015
Metadata
Show full item record
Collections
  • Institutt for klinisk og molekylær medisin [3280]
  • Publikasjoner fra CRIStin - NTNU [34842]
Original version
Journal of Infection 2015, 70(4):381-391   10.1016/j.jinf.2014.12.019
Abstract
Objectives:

Biomarkers for diagnosis and therapy efficacy in tuberculosis (TB) are requested. We have studied biomarkers that may differentiate between active and latent TB infection (LTBI), the influence of HIV infection and changes during anti-TB chemotherapy.

Methods:

Thirty-eight plasma cytokines, assessed by multiplex and enzyme immunoassays, were analyzed in patients with active TB before and during 24 weeks of anti-TB chemotherapy (n = 65), from individuals with LTBI (n = 34) and from QuantiFERON-TB (QFT) negative controls (n = 65). The study participants were grouped according to HIV status.

Results:

Plasma levels of the CXC chemokine IP-10 and soluble TNF receptor type 2 (sTNFr2) significantly differentiated active TB from the LTBI group, irrespective of HIV status. In the HIV-infected group the sensitivity and specificity was 100% for IP-10 with a cut-off of 2547 pg/mL. Plasma IP-10 declined gradually during anti-TB chemotherapy (12–24 weeks, p = 0.002) to a level comparable to LTBI and QFT negative control groups. sTNFr2 fluctuated throughout therapy, but was decreased after 12–24 weeks (p = 0.006).

Conclusions:

IP-10 distinguished with high accuracy active TB from LTBI irrespective of HIV infection and declined during anti-TB chemotherapy. Plasma IP-10 may serve as a diagnostic biomarker to differentiate between the stages of TB infection and for monitoring therapy efficacy.
Publisher
Elsevier
Journal
Journal of Infection

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit